[PDF] Top 20 R&D and productivity in the Indian pharmaceutical firms
Has 10000 "R&D and productivity in the Indian pharmaceutical firms" found on our website. Below are the top 20 most common "R&D and productivity in the Indian pharmaceutical firms".
R&D and productivity in the Indian pharmaceutical firms
... and Indian companies established themselves as suppliers of active pharmaceutical ingredients (APIs) and intermediates to ...domestic pharmaceutical companies have increased their allocation for ... See full document
22
R&D investment, productivity and rates of return: A meta analysis of the evidence on OECD firms and industries
... the R&D capital stock constitute useful avenues for future research (Griliches, 1979; Bitzer and Stephan, 2007; and Hall et ...whether productivity estimates differ systematically between studies ... See full document
61
R&D inputs and productivity growth in China
... year Y K L R&D expendiure R&D stock 1978 6579.7 23506 40152 96.82277 452.8661 1979 7079.8 25538 41024 109.2073 545.6923 1980 7632 27614 42360 109.113 638.4383 1981 8028 29625 43725 ... See full document
11
R&D and productivity: Estimating production functions when productivity is endogenous
... the R&D ...to R&D expenditures and the linear ...of R&D and already attained productivity on future productivity is an important step in the direction ... See full document
53
Is Europe a Laggard in Pharmaceuticals? R&D Joint Ventures, Patent Quality and R&D Productivity
... with R&D sourcing and joint ventures given that the Frascati Manual lacks clarity in its reference to these activities; it allows for external technical services to the industry but excludes sourcing of ... See full document
37
R&D Efficiency in High Tech Firms in China
... on R&D efficiency in both developed countries (Gao and Chou, 2015; Tsai and Wang, 2005) and developing countries (Hu, 2001; Seo et ...the R&D efficiency in Chinese firms usually ... See full document
22
Multi Product Firms, R&D, and Growth
... many firms and too few prod- ucts per firm; in addition, we find that under laissez-faire the total mass of varieties and productivity growth are inefficiently ...in R&D is accompanied by ... See full document
47
Efficiency and Ranking of Indian Pharmaceutical Industry: Does Type of Ownership Matter?
... the Indian pharmaceutical firms by computing their technical efficiency scores for the period 1991 to ...studied productivity and technical changes in the Indian pharmaceutical ... See full document
22
Pharmaceutical regulation in Europe and its impact on corporate R&D
... in R&D productivity, the pharmaceut- ical industry’s survival (let alone its continued growth prospects), at least in its current form, is in great jeop- ...viable R&D business ... See full document
9
Overcoming Innovation Limits through Outward FDI: The Overseas Acquisition Strategy of Indian Pharmaceutical Firms
... the Indian policy regime has succeeded in building local capability in pharmaceutical sector but it has also created a number of limitations in pushing forward firm’s productivity and technological ... See full document
27
Liberalization, Firm Size and R&D performance: A Firm Level Study of Indian Pharmaceutical Industry
... As firms of developing countries tend to have limited research capabilities to develop their indigenous technological capabilities, they resort to imports of technologies from ...in-house R&D ... See full document
31
Mergers, Acquisitions and Firms’ Performance: Experience of Indian Pharmaceutical Industry
... of pharmaceutical companies with a sample of 52 firms over the period of 2000-01 to 2007-08 by using the multi-directional structure-conduct-performance-policy ...selecting pharmaceutical industry ... See full document
16
Debt and profitability: evidence from Indian firms
... that firms presumably trade off against this substantial corporate tax ...the Indian context, Sukhtankar (2016) studies the effect of firm ownership structure on firm behavior and the economic outcomes of ... See full document
6
Productivity and Financial Structure: Evidence from Indian High Tech Firms
... The Indian electronics industry provides an ideal backdrop to explore this ...that firms in this industry are R&D intensive and the fact that R&D‐intensive firms ... See full document
24
MERGERS AND ACQUISITIONS IN INDIAN PHARMACEUTICAL INDUSTRY: A CASE STUDY ON MATRIX LAB
... in pharmaceutical market. Pharma MNCs have acquired Indian companies to maximise their capabilities in serving the global ...with Indian companies bring to the table new products, latest technology, ... See full document
12
R&D intensity and market valuation of firm: a study of R&D incurring manufacturing firms in India
... the Indian policy makers acknowledged that improved performance and efficiency is supposed to be a prerequisite for ...liberalization, firms are putting in particular efforts to acquire technological ... See full document
21
Factors affecting productivity of research based pharmaceutical companies following mergers and acquisitions
... of pharmaceutical drugs and to generate new molecular entities, many research-based companies take the liberty of undergoing ...research-based pharmaceutical companies, suddenly accumulate new resources ... See full document
19
Relationship Between Financial Structure and Productivity of Selected Indian Firms
... This has some interesting implications. First, the revenues accrued by the innovator producer originate from the increased efficiency in producing his good or service with the innovation. If the innovator-producer has ... See full document
7
Impact of R and D Intensity, Patents and Regulatory Filings on Export Intensity of Indian Pharmaceutical Industry
... that R and D activities had a greater role on growth, sustainability, profitability and export performance in drugs, chemicals and pharmaceutical ...2005, Indian pharmaceutical sector ... See full document
11
Prospects of Nanotechnology Development in the Health Sector in India
... Shasun Pharmaceuticals Limited is an Indian pharmaceutical company. It is a Chennai based firm. The company has formed a new 50:50 joint venture (JV) with Nanoparticle Biochem Inc. (NBI) which is partly ... See full document
17
Related subjects